Uncategorized

Sell to the Drug Patent Cliff: How Biopharma Packaging Companies Win Deals by Tying Serialization and Anti-Counterfeit Solutions to Drug Patent Loss of Exclusivity

Biopharma is entering a new kind of cliff—not the one in the pipeline, but the one in the P&L.
As patents expire and loss of exclusivity accelerates, the market doesn’t just get cheaper. It gets messier. Competitors don’t simply undercut pricing; t…

Sell to the Drug Patent Cliff: How Biopharma Packaging Companies Win Deals by Tying Serialization and Anti-Counterfeit Solutions to Drug Patent Loss of Exclusivity Read Post »

Biotechblog
Scroll to Top